How to assess and reduce Nitrosamine Contamination Risks in Peptide APIs
Recent years have seen drug recalls based on nitrosamine drug substance related impurities (NDSRIs), with medical agencies advising API manufacturers to implement risk assessment and mitigation strategies to meet safety and regulatory requirements. CDMOs often serve...
Going Large-scale with Manufacturing of Oligonucleotides
The growing number of oligonucleotide-based APIs is accompanied by an increasing need for efficient routes for their large-scale manufacturing. It is therefore essential to develop more efficient, more sustainable, and highly scalable manufacturing techniques. The...
More than white Powder and Reports
Bachem is a peptide and oligonucleotide manufacturer undergoing a steep growth curve together with our partners in pharmaceutical industry. Customer-related project management (PM) is a key contributor to this growth. Join this webinar to get insights about our PM...
Large-scale TIDES purification with MCSGP under GMP
Throughout industry the trend goes from producing batches to continuous production. Due to the increasing need for efficient methods to produce peptides and oligonucleotides on a large scale, Bachem was the first TIDES manufacturer to introduce Multicolumn...